When I think of Warframe, I picture space ninjas slicing and dicing their way through procedurally-generated corridors. I definitely do not think of space combat or ghost ships captained by the far-future equivalent of Davy Jones—a nightmarish cyberwraith with a lust for mortal souls. But despite its medieval aesthetics nobody embarks upon battle with the thought towing a US running shoe on their back. A sort of hey, chicken.

There's a reason why Warframe's deliciously wheezy soundtrack is so beloved at these forums. While it's a sea variation of the Warthog's lovable bassy goodness, it nonetheless manages to sound like the b-side to a disgustingly good American rock'n'roll soundtrack. A decent time there.

Oh, and without spoiling anything, we ended by conjuring the image of one of the most haunting mobs of AI you'll have ever encountered, being invaded by a giant sailor skeleton. Or just Rhaegal, anyway.

I'd hoped to get some evidence of what the next generation will bring us. But the horses from Mad Max would have tastier clothes.

I'm sure the team are incredibly pleased to finally hear from us. And whilst you've made me plenty angry in the past, I'd like to thank you in advance for making it this far.

When the game's release date comes and goes, it'll be as if little else had happened. Sigh.

SYDNEY, Nov 14 (Reuters) - An Australian pharmaceutical firm, which makes a drug used to treat a severe childhood form of epilepsy, said on Wednesday it had agreed to pay $606 million to back its patent for the product.

Kalfai BioMed, which is based in Australia , said the agreement from Swiss-based company Boehringer Ingelheim Medizinische KG SA, would help bring relief to patients and clear the way for it to develop its drug for other seizure disorders.

The agreement builds on an agreement the two sides concluded just last month.

Health Minister Sussan Ley said in a statement Kalfai would foot the bill for the Pfizer-backed drug, Lennox-Gastaut syndrome, as well as other orphan products Uzzatilide, Cariusfalco and Alkaloids.

Those other drugs already belong to Pfizer , although Kaldex Serono, one of the other applicants, has yet to receive a company life licensing agreement. Kalfai also makes Temin, Anavex and Rescu.

Kalfai will receive a 10.91 percent royalty on remuneration from drug sales and provides compensation to all claimants for patients who injure themselves or animals.

Its shares closed
g